Novo Nordisk Launches Low-Priced Insulin In US
Introduces Authorized Generics Of Its NovoLog And NovoLog Mix
Novo Nordisk says it is offering solutions to the unaffordability and inaccessibility of insulin by launching US authorized generics of its NovoLog and NovoLog Mix brands. The originator is also introducing a ‘My$99Insulin’ plan and an ‘immediate supply’ option to “help people with diabetes who need alternative solutions.”
